Shenzhen Weiguang Biological Products Co., Ltd. (SHE:002880)
China · Delayed Price · Currency is CNY 30.85
-0.01 (-0.03%)
Feb 13, 2026, 3:04 PM CST
SHE:002880 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,129 | 1,193 | 1,020 | 659.82 | 894.22 | 894.11 |
Other Revenue | 10.54 | 10.54 | 28.96 | 8.12 | 13.21 | 10.46 |
| 1,140 | 1,203 | 1,049 | 667.93 | 907.43 | 904.56 | |
Revenue Growth (YoY) | -2.33% | 14.75% | 56.98% | -26.39% | 0.32% | 10.12% |
Cost of Revenue | 656.81 | 699.32 | 615.26 | 427.02 | 536.52 | 568.22 |
Gross Profit | 483.18 | 503.87 | 433.24 | 240.91 | 370.91 | 336.35 |
Selling, General & Admin | 125.9 | 121.81 | 126.94 | 91.67 | 88.45 | 81.6 |
Research & Development | 46.58 | 49.05 | 63.62 | 35.87 | 47.59 | 45.1 |
Other Operating Expenses | 4.47 | 5.16 | 3.25 | -1.73 | 7.36 | 6.25 |
Operating Expenses | 194.75 | 180.1 | 191.31 | 124.47 | 144.51 | 131.57 |
Operating Income | 288.43 | 323.76 | 241.93 | 116.44 | 226.4 | 204.78 |
Interest Expense | -21.49 | -21.93 | -14.34 | -2.06 | -1.87 | -1.06 |
Interest & Investment Income | 10.13 | 7.92 | 8.03 | 8.85 | 8.91 | 8.36 |
Other Non Operating Income (Expenses) | -1.06 | -1.81 | -0.94 | -1.62 | -1.15 | -0.13 |
EBT Excluding Unusual Items | 276.01 | 307.95 | 234.68 | 121.62 | 232.29 | 211.96 |
Gain (Loss) on Sale of Investments | -13.93 | -14.05 | 2.23 | 14.33 | 0.74 | - |
Gain (Loss) on Sale of Assets | 0.16 | 0.21 | 0.06 | 0.04 | - | 0.07 |
Asset Writedown | -0.06 | -0.06 | -0.16 | -0.5 | - | -0.58 |
Other Unusual Items | 2.02 | 2.69 | 8.65 | 1.84 | 8.15 | 7.59 |
Pretax Income | 264.2 | 296.74 | 245.45 | 137.32 | 241.17 | 219.04 |
Income Tax Expense | 34.95 | 42.78 | 27.91 | 16.1 | 36.18 | 29.46 |
Earnings From Continuing Operations | 229.25 | 253.96 | 217.54 | 121.21 | 204.99 | 189.59 |
Minority Interest in Earnings | -0.57 | -0.44 | 1.11 | -3.69 | 0.44 | 0.81 |
Net Income | 228.68 | 253.52 | 218.65 | 117.52 | 205.44 | 190.4 |
Net Income to Common | 228.68 | 253.52 | 218.65 | 117.52 | 205.44 | 190.4 |
Net Income Growth | -8.57% | 15.95% | 86.06% | -42.80% | 7.90% | 11.12% |
Shares Outstanding (Basic) | 227 | 227 | 227 | 227 | 227 | 227 |
Shares Outstanding (Diluted) | 227 | 227 | 227 | 227 | 227 | 227 |
Shares Change (YoY) | 0.02% | 0.00% | 0.01% | -0.01% | 0.00% | 0.00% |
EPS (Basic) | 1.01 | 1.12 | 0.96 | 0.52 | 0.91 | 0.84 |
EPS (Diluted) | 1.01 | 1.12 | 0.96 | 0.52 | 0.91 | 0.84 |
EPS Growth | -8.59% | 15.94% | 86.05% | -42.79% | 7.90% | 11.12% |
Free Cash Flow | -28.74 | -77.73 | 69.08 | -326.17 | 6.06 | 114.76 |
Free Cash Flow Per Share | -0.13 | -0.34 | 0.30 | -1.44 | 0.03 | 0.51 |
Dividend Per Share | 0.200 | 0.200 | 0.400 | - | 0.200 | 0.179 |
Dividend Growth | - | -50.00% | - | - | 11.98% | 17.19% |
Gross Margin | 42.38% | 41.88% | 41.32% | 36.07% | 40.88% | 37.18% |
Operating Margin | 25.30% | 26.91% | 23.07% | 17.43% | 24.95% | 22.64% |
Profit Margin | 20.06% | 21.07% | 20.85% | 17.59% | 22.64% | 21.05% |
Free Cash Flow Margin | -2.52% | -6.46% | 6.59% | -48.83% | 0.67% | 12.69% |
EBITDA | 426.15 | 439.43 | 328.19 | 180.64 | 280.85 | 250.5 |
EBITDA Margin | 37.38% | 36.52% | 31.30% | 27.05% | 30.95% | 27.69% |
D&A For EBITDA | 137.73 | 115.67 | 86.26 | 64.2 | 54.45 | 45.72 |
EBIT | 288.43 | 323.76 | 241.93 | 116.44 | 226.4 | 204.78 |
EBIT Margin | 25.30% | 26.91% | 23.07% | 17.43% | 24.95% | 22.64% |
Effective Tax Rate | 13.23% | 14.42% | 11.37% | 11.73% | 15.00% | 13.45% |
Revenue as Reported | 1,140 | 1,203 | 1,049 | 667.93 | 907.43 | 904.56 |
Advertising Expenses | - | 0.31 | 0.45 | 0.28 | 0.18 | 0.34 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.